CD33和CD13表达与多发性骨髓瘤患者预后的关系

目的:探讨初诊多发性骨髓瘤(MM)患者中CD33和CD13的表达情况及其与患者预后的关系。方法:回顾性分析2014年1月至2020年1月初诊的121例MM患者中CD33和CD13的表达情况及CD33和CD13表达与患者预后的关系。结果:121例初诊MM患者中,CD33⁺组有30例(24.8%),CD13⁺组有12例(9.9%)。Kaplan-Meier分析显示,与CD33^-组比较,CD33⁺组MM患者的无进展生存(PFS)时间和总体生存(OS)时间显著缩短(PFS 17.5 vs 23个月,P=0.000;OS 18.5 vs 25个月,P=0.000);与CD13^-组比较,CD13⁺组MM患者的PFS时间和OS时间也显著缩短(PFS 21 vs 22个月,P=0.012;OS 25 vs 26个月,P=0.006)。Cox回归分析显示,CD33和CD13均是MM患者的独立预后不良因素(CD33:P=0.000;CD13:P=0.003)。结论:CD33和...

The Relationship between the Expressions of CD33 and CD13 and the Prognosis of Patients with Multiple Myeloma

Objective;To investigate the expressions of CD33 and CD13 in newly diagnosed multiple myeloma(MM)patients and its relationship with prognosis.Methods:It was retrospectively observed that the expression of CD33 and CD 13 in 121 MM patients who were newly diagnosed from January 2014 to January 2020,and the relationship between the expressions of CD33 and CD13 and patients prognosis was analyzed.Results:Among the 121 newly diagnosed MM patients,there were 30 patients(24.8%)in the CD33⁺group and 12 patients(9.9%)in the CD13⁺group.Kaplan-Meier analysis showed that,compared with the CD33^-group,the progression-free survival(PFS)time and overall survival(OS)time were significantly shortened in MM patients in CD33⁺group(PFS 17.5 vs 23 months,P=0.000;OS 18.5 vs 25 months,P=0.000);and the PFS time and OS time of MM patients in the CD13⁺group were also significantly shortened than those in CD13^-group(PFS 21 vs 22 months,P=0.012;OS 25 vs 26 months,P=0.006).Cox regression analysis showed that CD33 and CD 13 were independent adverse prognostic factors in MM patients(CD33:P=0.000;CD13:P=0.003).Conclusion:CD33 and CD 13 are prognostic risk factors in patients with MM.